Skip to main content

The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma

Molecular Biology Reports volume 40, pages 6525–6531 (2013)Cite this article

Abstract

Hepatocellular carcinoma is a primary malignancy of hepatocytes which accounts for 80 % of all primary liver cancers. DFNA5 has been identified as a tumor suppressor gene with an important role in several frequent forms of cancers, while little is known about its role in hepatocellular carcinoma. Through comparison of the DFNA5 protein expression in hepatocellular carcinoma cells (HepG2) with human fetal lung fibroblast cells (MRC5), we found that the DFNA5 protein expression in hepatocellular carcinoma cells was significantly lower than that in normal cells. The transfection of DFNA5 gene into HepG2 cells could increase DFNA5 protein expression, which subsequently led to inhibition of cell proliferation. Underlying mechanism study revealed that decreased proliferation was due to increased apoptosis and cell cycle arrest. In view of the important role of DFNA5 gene in carcinogenesis, these findings are expected to provide new understanding on development and treatment of human hepatocellular carcinoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Abrams P, Marsh JW (2010) Current approach to hepatocellular carcinoma. Surg Clin North Am 90(4):803–816. doi:S0039-6109(10)00045-9 10.1016/j.suc.2010.04.010

    PubMed  Article  Google Scholar 

  2. Tan YJ (2011) Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 17(44):4853–4857. doi:10.3748/wjg.v17.i44.4853

    PubMed  Article  CAS  Google Scholar 

  3. Cabibbo G, Craxi A (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14(4):352–355

    PubMed  CAS  Google Scholar 

  4. Toyota M (2005) Issa J Epigenetic changes in solid and hematopoietic tumors. Seminars in oncology, In, p 521

    Google Scholar 

  5. Zhang YJ, Wu HC, Yazici H, Yu MW, Lee PH, Santella RM (2012) Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B1 exposure. World J hepatol 4(5):169

    PubMed  Article  CAS  Google Scholar 

  6. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A (2007) Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Bri J cancer 97(9):1260–1265

    Article  CAS  Google Scholar 

  7. Saelee P, Petmitr S, Wongkham S, Chariyalertsak S, Homcha-cm P (2010) Detection of DNA methylation of p16INK4a in hepatocellular carcinoma by methylation specific-polymerase chain reaction. Thai Cancer J 29(2):72–79

    Google Scholar 

  8. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9(14):5295–5298

    PubMed  CAS  Google Scholar 

  9. Jain S, Chang TT, Hamilton JP, Lin SY, Lin YJ, Evans AA, Selaru FM, Lin PW, Chen SH, Block TM (2011) Methylation of the CpG Sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS ONE 6(11):e26799

    PubMed  Article  CAS  Google Scholar 

  10. Jain S, Chen S, Chang KC, Lin YJ, Hu CT, Boldbaatar B, Hamilton JP, Lin SY, Chang TT, Chen SH (2012) Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS ONE 7(4):e35789

    PubMed  Article  CAS  Google Scholar 

  11. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, Cho JW, Park YM, Jung G (2008) Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135(6):2128–2140

    PubMed  Article  CAS  Google Scholar 

  12. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163(4):1371

    PubMed  Article  CAS  Google Scholar 

  13. Wang X, Meng X, Sun X, Liu M, Gao S, Zhao J, Pei F, Yu H (2009) Wnt/β-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle 8(10):1567–1570

    PubMed  Article  CAS  Google Scholar 

  14. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M (2009) Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9(1):125

    PubMed  Article  Google Scholar 

  15. Tanaka S, Shiraha H, Nakanishi Y, Nishina SI, Matsubara M, Horiguchi S, Takaoka N, Iwamuro M, Kataoka J, Kuwaki K (2012) Runt-related transcription factor 3 reverses epithelial–mesenchymal transition in hepatocellular carcinoma. Int J Cancer 131:2537–2546

    PubMed  Article  CAS  Google Scholar 

  16. Van Laer L, Huizing EH, Verstreken M, Van Zuijlen D, Wauters JG, Bossuyt PJ, Van de Heyning P, McGuirt WT, Smith RJH, Willems PJ (1998) Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet 20(2):194–197

    PubMed  Article  Google Scholar 

  17. Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, Nishikawa N, Watanabe Y, Sasaki Y, Abe T (2006) Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci 98(1):88–95

    Article  Google Scholar 

  18. Kim M, Chang X, Yamashita K, Nagpal J, Baek J, Wu G, Trink B, Ratovitski E, Mori M, Sidransky D (2008) Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene 27(25):3624–3634

    PubMed  Article  CAS  Google Scholar 

  19. Kim MS, Lebron C, Nagpal JK, Chae YK, Chang X, Huang Y, Chuang T, Yamashita K, Trink B, Ratovitski EA (2008) Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophy Res Commu 370(1):38–43

    Article  CAS  Google Scholar 

  20. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T (2010) Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Tr 122(3):699–710

    Article  Google Scholar 

  21. De Beeck KO, Van Camp G, Thys S, Cools N, Callebaut I, Vrijens K, Van Nassauw L, Van Tendeloo VFI, Timmermans JP, Van Laer L (2011) The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. Eur J Human Genet 19(9):965–973

    Article  Google Scholar 

  22. Searle J, Harmon B, Bishop C, Kerr J (2008) The significance of cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol 2(1):77–96

    Article  Google Scholar 

  23. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5(3):231–237

    PubMed  CAS  Google Scholar 

  24. Kaufmann T, Strasser A, Jost P (2011) Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19(1):42–50

    PubMed  Article  Google Scholar 

  25. Higaki K, Yano H, Kojiro M (1996) Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 149(2):429

    PubMed  CAS  Google Scholar 

  26. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31–37

    PubMed  Article  Google Scholar 

  27. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59(20):5356–5364

    PubMed  CAS  Google Scholar 

  28. Ryan AE, Shanahan F, O’Connell J, Houston AM (2006) Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 5(3):246–249

    PubMed  Article  CAS  Google Scholar 

  29. Kykalos S, Mathaiou S, Karayiannakis AJ, Patsouras D, Lambropoulou M, Simopoulos C (2012) Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer 43(2):224–228

    PubMed  Article  CAS  Google Scholar 

  30. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR (2003) A unified model for apical caspase activation. Mol Cell 11(2):529–541

    PubMed  Article  CAS  Google Scholar 

  31. Stennicke HR, Jürgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D (1998) Pro-caspase-3 is a major physiologic target of caspase-8. J Biological Chem 273(42):27084–27090

    Article  CAS  Google Scholar 

  32. Fulda S (2009) Caspase-8 in cancer biology and therapy. Cancer Lett 281(2):128–133

    PubMed  Article  CAS  Google Scholar 

  33. Lavrik I, Krammer P (2011) Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 19(1):36–41

    PubMed  Article  Google Scholar 

  34. Bucher N, Britten C (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Bri J cancer 98(3):523–528

    Article  CAS  Google Scholar 

  35. Zhang L, Ruan J, Yan L, Li W, Wu Y, Tao L, Zhang F, Zheng S, Wang A, Lu Y (2012) Xanthatin induces cell cycle arrest at G2/M checkpoint and apoptosis via disrupting NF-κB pathway in A549 non-small-cell lung cancer cells. Molecules 17(4):3736–3750

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This project is supported by Grants from the National Natural Science Foundation of China (No. 30872510, 81200320, 81272534, 81260349); the Natural Science Foundation of Hubei Province (No. 2008CDB127), and the Natural Science Foundation of Shanghai (No. 064119620 10411968400).

Author information

Affiliations

  1. Department of General Surgery, Shanghai East Hospital, Tongji University School of Medicine, No 150 Jimo Road, Pudong New Area, Shanghai, 200120, China

    Cong-Jun Wang, Lin Tang, Dong-Wei Shen, Chao Wang, Qiong-Ying Yuan, Wei Gao, Yong-Kun Wang & Hui Zhang

  2. Department of Oncology Surgery, The Affiliated Hospital of Hainan Medical College, Haikou, 570102, Hainan Province, China

    Rong-Hua Xu

Authors
  1. Cong-Jun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Wei Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qiong-Ying Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yong-Kun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rong-Hua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rong-Hua Xu or Hui Zhang.

Additional information

Cong-Jun Wang and Dong-Wei Shen are co-first authors.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wang, CJ., Tang, L., Shen, DW. et al. The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma. Mol Biol Rep 40, 6525–6531 (2013). https://doi.org/10.1007/s11033-013-2581-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-013-2581-8

Keywords

  • DFNA5
  • Hepatocellular carcinoma
  • Apoptosis
  • Cell cycle arrest